# Lexeo Therapeutics, Inc. (LXEO) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Lexeo Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/LXEO/mda/fy2025/): filed 2026-03-30; accession 0001193125-26-132085 (https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/LXEO/mda/fy2024/): filed 2025-03-24; accession 0000950170-25-043486 (https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm)
- [FY 2023 MD&A](/company/LXEO/mda/fy2023/): filed 2024-03-11; accession 0000950170-24-028941 (https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/lxeo-20231231.htm)

Back to /company/LXEO/